## Contents – click on physician name to link to his/her publications

<table>
<thead>
<tr>
<th>Physician</th>
<th>Publications</th>
<th>Presentations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chirag Amin, MD</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td>Anne Greist, MD</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td>Sweta Gupta, MD</td>
<td>3</td>
<td></td>
</tr>
<tr>
<td>Brandon Hardesty, MD</td>
<td>4</td>
<td></td>
</tr>
<tr>
<td>Mark Heiny, MD, PhD</td>
<td>4</td>
<td></td>
</tr>
<tr>
<td>Jennifer Maahs, PNP</td>
<td>5</td>
<td></td>
</tr>
<tr>
<td>Charles Nakar, MD</td>
<td>6</td>
<td></td>
</tr>
<tr>
<td>Angeli Rampersad, MD</td>
<td>8</td>
<td></td>
</tr>
<tr>
<td>Amy Shapiro, MD</td>
<td>9</td>
<td></td>
</tr>
<tr>
<td>Anand Tandra, MD</td>
<td>16</td>
<td></td>
</tr>
<tr>
<td>Other IHTC Staff</td>
<td>16</td>
<td></td>
</tr>
</tbody>
</table>

Since 2010
Chirag Amin, MD

**Publications**

Govani M, **Amin C** et al. Recurrence of monoclonal IgA lambda glomerulonephritis in kidney allograft associated with multiple myeloma. Clinical Nephrology 2014; accepted, in press.


Anne Greist, MD

**Publications**


**Presentations**

Asirwa FC, **Greist A**, Roberson C. AMPATH Hematology: Collaboration between Indiana Hemophilia & Thrombosis Center (IHTC), Indiana University and Moi University, Eldoret (Kenya). Poster presentation at the 2nd Global Sickle Cell Disease Network, March 2012, Atlanta, GA.

Sweta Gupta, MD

Publications


Presentations


Gupta S. Comparison of quality of life in an Amish and Non Amish cohort affected with Von Willebrand disease. Poster presentation at Scientific and Standardization Committee (SSC) Annual Meeting, June 2012, Liverpool, UK.
**Gupta S.** Effect of Secondary Prophylaxis versus Episodic Treatment on Range of Motion of a Target Joint in Hemophilia Patients. *Poster presentation* at Thrombosis and Hemostasis Summit of North America (THSNA), May 2012, Chicago, IL.

**Brandon Hardesty, MD**

*Presentations*

**Hardesty B.** Evaluation for Hypercoagulable States. *Oral presentation* at Elkhart General Hospital. April 2014, Elkhart, IN.

**Hardesty B.** Basics of Sickle Cell Disease and Hope on the Horizon. *Oral presentation* at 2014 Indiana Sickle Cell Conference. April 2014, Indianapolis, IN.

**Hardesty B.** Patterns of Lymphocyte Expansion After Minimal Intensity Allogenic Stem Cell Transplant. *Oral Presentation* at Indiana University Simon Cancer Center. November 2012. Indianapolis, IN.


**Mark Heiny, MD, PhD**

*Publications*


*Presentations*


Jennifer Maahs, PNP

Publications


Presentations


Maahs J. Developing Care in Developing Countries. Oral presentation at International Society of Thrombosis and Hemostasis. June 29-July 4, 2013; Amsterdam, Holland, The Netherlands.


Maahs J. Management of Patients with VWD. Oral presentation at National Hemophilia Foundation (NHF) 64th Annual Meeting. November 2012, Orlando, FL.


Charles Nakar, MD

Publications


Presentations


Angeli Rampersad, MD

Publications


Presentations


Hampton K., Roberson C., Rampersad A., Duncan N., Sealls W., Shapiro A.. Indiana’s Newborn Hemoglobinopathy Screening Program: Structure and Data from Initial 3 Years: The Sickle SAFE Program. Oral presentation at Sickle Cell Disease Association of America (SCDAA) 40th Annual Convention. September 2012, Baltimore, Maryland.

Hampton K., Roberson C., Rampersad A., Hulbert M.L., Shapiro A. The Indiana Sickle-SAFE Program. Poster presentation at Sickle Cell Disease Association of America (SCDAA) 38th Annual Convention, September 2010, Washington, DC.
Amy Shapiro, MD

**Publications**


Shapiro AD, Neufeld EJ, Blanchette V, Salaj P, Gut RZ, Cooper DL. Safety of recombinant activated factor VII (rFVIIa) in patients with congenital haemophilia with inhibitors: overall rFVIIa exposure and intervals following high (>240 mug kg(-1))(1)) rFVIIa doses across clinical trials and registries. Haemophilia 2014;20:e23-31.


Gruppo R, Kessler C, Neufeld E, Shapiro A, Cooper D, Carr Jr. M. Abstract 17P35: A comparison of prescribed and actual recombinant factor VIIa (rFVIIa) dosing in pediatric versus adult patients with...
congenital hemophilia with inhibitors (CHwI): analysis of the dosing observations study in hemophilia (DOSE). Haemophilia 2010;16(Suppl 4):73.


Shapiro AD, Neufeld EJ, Cooper DL. Safety of exposure to recombinant activated FVII (rFVIIa) doses in patients with hemophilia and inhibitors (CHwI) to factors VIII or IX. ASH Annual Meeting Abstracts 2010;116(21):3675.


Presentations
Not listed.
Anand Tandra, MD

Publications


Presentations

Other IHTC Staff

Publications


Presentations
Duncan N., Krishnan S., Kronenberger W., Shapiro A. Adherence to Prophylactic Treatment in Hemophilia as Measured Using the VERITAS-Pro and Factor Doses Administered and Annual Bleed Rate (ABR). Poster presentation at International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Annual Meeting, June 2014, Montreal, QC, Canada. Presented by S. Krishnan.

Duncan N., Krishnan S., Kronenberger W., Shapiro A. Adherence to Prophylactic Treatment in Hemophilia as Measured Using the VERITAS-Pro and Factor Doses Administered and Annual Bleed Rate (ABR). Poster presentation at World Federation of Hemophilia (WFH) World Congress, May 2014, in Melbourne, VIC, Australia.

Bloom E., Hampton K. Expansion of the Sickle SAFE Program from Birth to 5. Oral presentation at Region 4 Genetic Collaborative Regional Meeting, April 2014, Lansing, MI.

Bloom E. School Accommodations for Sickle Cell Disease. Oral presentation at Regional Conferences for School Nurses hosted by Indiana State Department of Health, Various Indiana locations, April 2014.

Nakar C, Manco-Johnson MJ, Lail A, Donfield S, Maahs J, Chong Y, Blades T, Shapiro A. Prompt Immune Tolerance Induction at Inhibitor Diagnosis Regardless of Titer May Increase Overall Success


Hampton K. What All Early Care and Educational Professionals Need to Know About Sickle Cell Disease. Oral presentation at 2013 Indiana Early Childhood Conference, April 2013.


Asirwa FC, Greist A, Roberson C. AMPATH Hematology: Collaboration between Indiana Hemophilia & Thrombosis Center (IHTC), Indiana University and Moi University, Eldoret (Kenya). Poster presentation at the 2nd Global Sickle Cell Disease Network, March 2012, Atlanta, GA.


Hampton K. Newborn Screening Follow-up in Indiana for Hemoglobinopathies. Oral presentation at Region 4 Genetics Collaborative. September 2012, Lansing, MI.

Hampton K., Roberson C., Rampersad A., Duncan N., Sealls W., Shapiro A. Indiana’s Newborn Hemoglobinopathy Screening Program: Structure and Data from Initial 3 Years: The Sickle SAFE Program. Oral presentation at Sickle Cell Disease Association of America (SCDAA) 40th Annual Convention. September 2012, Baltimore, Maryland.


Hampton K. Indiana Sickle-SAFE NBS Program. Oral presentation at South Bend Sickle Cell Conference. October 2011, South Bend, IN.

Hampton K. Indiana Sickle-SAFE NBS Program. Oral presentation at South Bend Sickle Cell Conference. October 2010, South Bend, IN.

Hampton K., Roberson C., Rampersad A., Hulbert M.L., Shapiro A. The Indiana Sickle-SAFE Program. Poster presentation at Sickle Cell Disease Association of America (SCDAA) 38th Annual Convention, September 2010, Washington, DC.


Duncan N., Kronenberger W., Roberson C., Shapiro A.. Predictors of Nonadherence to Prophylactic Treatment of Hemophilia as Measured Using the VERITAS-Pro. Poster presentation at National Conference on Blood Disorders in Public Health, March 2010, Atlanta, GA.


Duncan N. Evaluating Adherence to Hemophilia Treatment Regimens. Oral presentation at Hemophilia of Georgia (HOG) Annual Meeting. February 2010, Atlanta, GA.